Wilderness medical emergencies

BTG Specialty Pharmaceuticals Calls on Consumers and Retailers to Consider the Facts About Venom Extractors

Retrieved on: 
Tuesday, April 20, 2021
Wilderness medical emergencies, Medical specialties, Clinical medicine, Venomous snakes, Medicine, Animal attacks, Medical emergencies, Neglected tropical diseases, Snakebite, Snake venom, Antidote, Snake

These experts in the treatment of snakebites unanimously agree that venom extractors should not be used to treat snakebites.

Key Points: 
  • These experts in the treatment of snakebites unanimously agree that venom extractors should not be used to treat snakebites.
  • \xe2\x80\x9cBecause the extractors could cause an injury pattern, it goes against the physician\xe2\x80\x99s oath to do no harm.
  • The only effective and safe first aid treatment for a snakebite is a swift trip to the hospital.
  • Our current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.

$1.58 Billion Anti-venom Market - Global Growth, Trends, COVID-19 Impact, and Forecasts 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 3, 2021
Pharmaceutical, Health, Other Health, Fictional characters, Clinical medicine, Marvel Comics characters, Antitoxins, Wilderness medical emergencies, Antivenom, Animal attacks, CSL Limited, Snakebite, Sigma-Aldrich, Merck Group, Boehringer Ingelheim

The "Anti-venom Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anti-venom Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
  • There is a significant increase in the number of deaths reported due to snake bites during the COVID-19 pandemic in few areas.
  • Owing to the numerous advantages key players dealing in the anti-venom market are focusing to develop polyvalent antivenoms.
  • The major market players operating in the anti-venom market include BTG PLC, Pfizer Inc., Merck KGaA (Sigma Aldrich), Boehringer Ingelheim, and CSL Limited among others.

Ophirex Receives Wellcome Trust Award to Advance Clinical Development of Novel Snakebite Treatment

Retrieved on: 
Monday, March 2, 2020
Biotechnology, Pharmaceutical, Health, Medicine, Medical specialties, RTT, Clinical medicine, Wilderness medical emergencies, Animal attacks, Medical emergencies, Venomous snakes, Snakebite, Antivenom, Antidote

The award will fund manufacturing of oral and IV varespladib, Ophirexs lead drug candidate, for use in Ophirexs upcoming, potentially pivotal clinical trial studies.

Key Points: 
  • The award will fund manufacturing of oral and IV varespladib, Ophirexs lead drug candidate, for use in Ophirexs upcoming, potentially pivotal clinical trial studies.
  • Ophirex is developing varespladib as a first-in-class, toxin-targeting antidote for snakebite, with the ultimate goal of safe and rapid administration to snakebite victims in the out-of-hospital setting where without immediate access to antivenom most snakebite deaths occur.
  • By inhibiting the progression of a key venom component called sPLA2, varespladib could mitigate many of the most common, immediately life-threatening effects of snakebite envenoming.
  • Ophirex was founded via the work of expedition doctor Matthew Lewin, MD, PhD, with support from musician and entrepreneur Jerry Harrison.

New Research Validates Clinical Value of Treating Copperhead Envenomation with CroFab®

Retrieved on: 
Tuesday, March 5, 2019
Medical specialties, Fictional characters, Agkistrodon, Antitoxins, Crotalidae polyvalent immune fab, Medicine, Venomous snakes, Wilderness medical emergencies, RTT, Snakebite, Copperhead, Agkistrodon contortrix mokasen

Additionally, it demonstrates that the effect of CroFab found in the Copperhead trial is clinically significant."

Key Points: 
  • Additionally, it demonstrates that the effect of CroFab found in the Copperhead trial is clinically significant."
  • Copperhead envenomations are often thought to be less severe than other North American Pit Viper snakebites.
  • This new data continues to support our indicated use by showing that patients bitten by copperheads recover limb function faster when treated with CroFab.
  • The researchers performed a post-hoc, secondary analysis of two BTG-sponsored trials of CroFab in patients suffering copperhead envenomation.